ClinicalTrials.gg
Not yet recruitingNCT06409273HOMEUpdated May 14, 2024

Hybrid Course Assessment and Evaluation

An interventional study of Hybrid course on medical thesis for post graduates general practice students and Face-to-face teaching on medical thesis for post graduates general practice students in Education, Medical, sponsored by Research on Healthcare Performance Lab U1290. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Research on Healthcare Performance Lab U1290 · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The academic training of French postgraduate students in general practice (E3CMG) is facing a challenge due to the increasing gap between the number of students and the available teaching hours. To accommodate the growing number of students, asynchronous acquisition of knowledge prior to a reduced face-to-face teaching would maintain the capacity to provide socio-constructivist teaching useful for developing problem-solving skills (i.e. thesis design and feasibility assessment). The main objective of this randomized controlled trial is to evaluate the effect of hybrid versus face-to-face socio-constructivist teaching on French E3CMG course assessment and evaluation.

Read the detailed description

The E3CMG will be invited to attend one of the two teaching days in accordance with the usual university procedure. They will be gathered in an amphitheater at the start of the teaching session (9:00 a.m.), where they will receive oral and written information about the study. Blocked randomization with randomly selected block sizes will be performed among students who have signed a written consent to participate in the study. Non-participants in the study will be assigned to one of the two teaching formats without randomization and respecting the need to achieve close class sizes. Their teaching assessments will not be extracted and analyzed as part of the study.

This late randomization procedure makes it possible to

  • allow students to change teaching day without regard to the study
  • avoid contamination bias caused by some students accessing the asynchronous interactive course before class
  • ensure compliance with the study protocol (systematic access to the asynchronous interactive course by students in the intervention group)
  • Control the time spent on the asynchronous interactive course to ensure that the time spent by students actually corresponds to that stated in the protocol.
  • To limit missing data management procedures: data collection on the day of teaching, and randomization only of students present on the day of teaching (limits attrition bias).

The 4 teachers on the first teaching day will be randomly assigned to the groups (May 14). If they take part in the second teaching day (05/21), they will teach in the other group in order to minimize a bias in the evaluation of the main judgment criterion linked to teacher quality.

The study begins on May 14, 2024 or May 21, 2024, depending on the participant's assigned teaching day, and ends on 11/14/2024. The maximum duration of participation in the study is therefore 6 months. The student's actual participation is 1 day, as data collection on 14/11 is automated and does not require any intervention by the participant.

No health data will be collected. Data will be collected via a self-administered questionnaire with a randomized order of questions at the end of the teaching day, and at 6 months via the university's database of thesis forms.

The number of participants to be included in the study is 72 per arm. This is necessary to demonstrate a difference in the primary endpoint of 10%, with a standard deviation of 4 points, an alpha risk of 5%, and a statistical power of 85%, for a two-tailed t-test of comparison of observed means. The theoretical maximum number of students included in the study was 83 per group, allowing for a 13% refusal rate (n=22 students).

A two-sided superiority test will be conducted, with a multivariate analysis and sensitivity analysis. To account for multiple comparisons regarding secondary objectives, a fixed sequence procedure will be performed. Once one hypothesis is tested and found to be not significantly different from the null hypothesis, all subsequent tests and results will be considered as explanatory. The secondary objectives described below are classified according to this procedure.

02

Conditions studied

  • Education, Medical

Keywords

  • Medical education
  • Students
  • dissertations, academic
  • Evaluation studies
  • Educational measurement
03

In context

Lead sponsor

Research on Healthcare Performance Lab U1290 is the lead sponsor of 8 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Postgraduate general practice students registered for assessed course.

Exclusion criteria

Exclusion Criteria:

  • Unsigned written consent to participate after oral and written information
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Intervention

    Hybrid course : asynchronous online interactive course (2h30, 45%) followed by face-to-face socio constructivist teaching (3h00, 55%)

    Other: Hybrid course on medical thesis for post graduates general practice students

  • Active comparator
    Control

    Face-to-face socio constructivist teaching (100%) (5h30)

    Other: Face-to-face teaching on medical thesis for post graduates general practice students

Interventions

  • OtherHybrid course on medical thesis for post graduates general practice students

    Students randomised to the intervention group will log on to interactive online teaching for a maximum time of 2.5 hours, and then follow face-to-face socio-constructivist teaching in small groups (n=22 max), building on the knowledge they have acquired. The aim of this peer-to-peer face-to-face teaching is to develop problem-solving skills.

  • OtherFace-to-face teaching on medical thesis for post graduates general practice students

    Students randomised to the control group will be taught entirely face-to-face in small groups (n=22 max). The course duration and teaching objectives are identical to those of the intervention group. Student consent and randomization will be carried out on the morning of the course to avoid contamination and attrition bias.

06

What researchers measure

Primary outcomes

  1. Self-assessment score for learning outcomes

    Sum of self-assessment score for knowledge (10 points) and self-assessment score for skills (10 points). Maximum value = 20, Minimum Value = 0. Higher score means a better outcome.

    Time frame: At the end of the teaching day

Secondary outcomes

  1. Overall satisfaction score

    Sum of the satisfaction score for knowledge-related learning objectives (satisfaction score 1, 10 points) and the satisfaction score for skill-related learning objectives (satisfaction score 2, 10 points). Maximum value = 20, Minimum Value = 0. Higher score means a better outcome.

    Time frame: At the end of the teaching day

  2. Self-assessment score for knowledge (10 points)

    10-point score based on a questionnaire completed by students to assess knowledge acquisition. Maximum value = 10, Minimum Value = 0. Higher score means a better outcome.

    Time frame: At the end of the teaching day

  3. Self-assessment score for skills (competencies) (10 points)

    10-point score based on a questionnaire completed by students to assess problem-solving skills acquisition. Maximum value = 10, Minimum Value = 0. Higher score means a better outcome.

    Time frame: At the end of the teaching day

  4. Satisfaction score 1

    10-point score for student satisfaction regarding knowledge-related learning objectives. Maximum value = 10, Minimum Value = 0. Higher score means a better outcome.

    Time frame: At the end of the teaching day

  5. Satisfaction score 2

    10-point score for student satisfaction regarding skills-related learning objectives. Maximum value = 10, Minimum Value = 0. Higher score means a better outcome.

    Time frame: At the end of the teaching day

  6. Submitting a thesis form

    A thesis form is a document submitted by students to the university department of general medicine for proofreading before validation concerning the problematization and feasibility of the project. The course evaluated is likely to improve the time taken to submit the thesis form.

    Time frame: 6 months after the course

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interest on medical education. Data or samples shared will be coded.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data requests can be submitted immediatly after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.

Access criteria: Approval of the request by Pierre-Yves Meunier (principal investigator) and Marion-Lamort Bouché (study director) and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party. For more information or to submit a request, please contact pierre-yves.meunier@univ-lyon1.fr

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2024; primary completion for May 2024, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2024
First posted
May 10, 2024
StartEst.
May 14, 2024
Primary completionEst.
May 21, 2024
CompletionEst.
Nov 14, 2024
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06409273
Lead sponsor
Research on Healthcare Performance Lab U1290
Responsible party
Sponsor
First posted
May 10, 2024
Start date
May 14, 2024 (estimated)
Primary completion
May 21, 2024 (estimated)
Completion
Nov 14, 2024 (estimated)
Last update
May 14, 2024

Study contacts

Pierre-Yves Meunier, MD
Contact
pierre-yves.meunier@univ-lyon1.fr
+33658930614
Marion Lamort-Bouché, MD, PhD
Contact
marion.lamort-bouche@univ-lyon1.fr
Rémy Boussageon, MD, PhD
study chair · Lyon 1 University & LBBE UMR 5558, CNRS
Marion Lamort-Bouché, MD, PhD
study director · Research on Healthcare Performance Lab U1290, Inserm
Pierre-Yves Meunier, MD
principal investigator · University Lyon 1
Sophie Schlatter, PhD
study chair · Research on Healthcare Performance Lab U1290, Inserm

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion